Europe - FRA:VX1 - US92532F1003 - Common Stock
VX1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 79 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making VX1 a very profitable company, without any liquidiy or solvency issues. VX1 is growing strongly while it is still valued neutral. This is a good combination! With these ratings, VX1 could be worth investigating further for growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 15.13% | ||
ROE | 21.18% | ||
ROIC | 15.66% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 38.77% | ||
PM (TTM) | 31.86% | ||
GM | 86.11% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.52 | ||
Quick Ratio | 2.16 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 24.13 | ||
Fwd PE | 19.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.94 | ||
EV/EBITDA | 21.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
FRA:VX1 (10/15/2025, 5:05:17 PM)
353.775
+0.92 (+0.26%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 24.13 | ||
Fwd PE | 19.66 | ||
P/S | 9.18 | ||
P/FCF | 29.94 | ||
P/OCF | 27.24 | ||
P/B | 6.1 | ||
P/tB | 6.7 | ||
EV/EBITDA | 21.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 15.13% | ||
ROE | 21.18% | ||
ROCE | 22.25% | ||
ROIC | 15.66% | ||
ROICexc | 23.06% | ||
ROICexgc | 25.99% | ||
OM | 38.77% | ||
PM (TTM) | 31.86% | ||
GM | 86.11% | ||
FCFM | 30.65% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 173.52% | ||
Cap/Sales | 3.04% | ||
Interest Coverage | 260.41 | ||
Cash Conversion | 83.13% | ||
Profit Quality | 96.21% | ||
Current Ratio | 2.52 | ||
Quick Ratio | 2.16 | ||
Altman-Z | N/A |